The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 04, 2021

Filed:

Jun. 03, 2016
Applicant:

H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US);

Inventor:

Scott Antonia, Land O'Lakes, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 31/00 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); A61K 45/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 39/0011 (2013.01); A61K 39/001139 (2018.08); A61K 39/39541 (2013.01); A61K 39/39558 (2013.01); A61K 45/05 (2013.01); A61P 11/00 (2018.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/5152 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); A61K 2300/00 (2013.01); C07K 2317/76 (2013.01);
Abstract

A method is disclosed for treating a cancer in a subject. The method comprises administering to the subject a composition comprising a therapeutically effective amount of a checkpoint inhibitor and a therapeutically effective amount of a tumor vaccine. In some embodiments, the tumor vaccine comprises radiated autologous tumor cells and a cell line engineered to express GM-CSF and CD40 ligand. In some embodiments, the checkpoint inhibitor comprises an anti-PD-1 antibody (e.g., BMS 936558), anti-PD-L1 antibody (e.g., cloneM1H1), anti-CTLA-4 antibody (e.g., Ipilimumab, BMS), or any combination thereof.


Find Patent Forward Citations

Loading…